Loxo Oncology to Present Updated LOXO-101 Adult Ph

– Company to Host Investor Conference Call and Webcast on Monday, December 19, 2016 –

STAMFORD, Conn., Dec. 12, 2016 (GLOBE NEWSWIRE) -- Loxo Oncology, Inc. (Nasdaq: LOXO ), a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, today announced that the abstract titled "Clinical safety and activity from a phase 1 study of LOXO-101, a selective TRKA/B/C inhibitor, in solid-tumor patients with NTRK gene fusions" has been accepted for oral presentation at the European Society for Medical Oncology (ESMO) Asia Congress, taking place December 16-19, 2016 in Singapore. Data from this trial were last presented at the American Association for Cancer Research (AACR) Annual Meeting in April 2016. The presentation will include an efficacy and durability update for enrolled patients with TRK fusions.

The schedule for the presentation is as follows:

Presentation Session Date & Time : December 18, 2016, 4:30 p.m. to 6:00 p.m. SGT Title : Clinical safety and activity from a phase 1 study of LOXO-101, a selective TRKA/B/C inhibitor, in solid-tumor patients with NTRK gene fusions Abstract Number : 150O Session : Developmental Therapeutics, Proffered Paper Session (oral presentation) Presenter : Todd Bauer, M.D., Associate Director, Drug Development; Principal Investigator, Sarah Cannon Research Institute

Conference Call and Webcast In conjunction with ESMO Asia, Loxo Oncology will be hosting a conference call and live webcast with slides and Q&A on December 19, 2016 at 8:00 a.m. ET to discuss the LOXO-101 Phase 1 data and provide a comprehensive program and pipeline update. The company anticipates that the conference call and webcast will last 60-90 minutes. To participate in the conference call, please dial (877) 930-8065 (domestic) or (253) 336-8041 (international) and refer to conference ID 16640119. A live webcast of the presentation will be available at  http://ir.loxooncology.com/ . A replay of the webcast will be available shortly after the conclusion of the call and archived on the company's website for 30 days following the call.

About Loxo Oncology Loxo Oncology is a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers. Our pipeline focuses on cancers that are uniquely dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer with dramatic effect. We believe that the most selective, purpose-built medicines have the highest probability of maximally inhibiting the intended target, thereby delivering best-in-class disease control and safety. Our management team seeks out experienced industry partners, world-class scientific advisors and innovative clinical-regulatory approaches to deliver new cancer therapies to patients as quickly and efficiently as possible. For more information, please visit the company's website at  www.loxooncology.com .

Contacts for Loxo Oncology, Inc.

Company: Jacob S. Van Naarden Chief Business Officer jake@loxooncology.com

Investors: Peter Rahmer The Trout Group, LLC 646-378-2973 prahmer@troutgroup.com

Media: Dan Budwick Pure Communications, Inc. 973-271-6085 dan@purecommunicationsinc.com